Drug intelligence / Profile preview

cenplacel

Development stage: Phase 2
Lead developer: Celularity
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intramuscular

Overview

Cenplacel (PDA-002) is an allogeneic, mesenchymal-like cell therapy derived from full-term human placental tissue, developed by Celularity. It is engineered to provide angiogenic and tissue regenerative properties, specifically for treating patients with peripheral arterial disease (PAD) and diabetic foot ulcers (DFU). The therapy works by potentially improving peripheral perfusion and promoting ulcer healing through the action of mesenchymal stromal cell-like properties. It is administered via intramuscular injection in combination with standard care.

Other names: PDA-002PDA002PDA 002human placenta-derived cells

Beyond the preview

Go deeper on cenplacel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cenplacel.

Explore the full profile